BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dakwar GR, Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible? Adv Drug Deliv Rev 2017;108:13-24. [PMID: 27422808 DOI: 10.1016/j.addr.2016.07.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Haegebaert RM, Kempers M, Ceelen W, Lentacker I, Remaut K. Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer. European Journal of Pharmaceutics and Biopharmaceutics 2022;172:16-30. [DOI: 10.1016/j.ejpb.2022.01.002] [Reference Citation Analysis]
2 Lee G, Han S, Inocencio I, Cao E, Hong J, Phillips ARJ, Windsor JA, Porter CJH, Trevaskis NL. Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties. Mol Pharmaceutics 2019;16:4987-99. [DOI: 10.1021/acs.molpharmaceut.9b00855] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
3 Lemoine L, Sugarbaker P, Van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. International Journal of Hyperthermia 2017;33:582-92. [DOI: 10.1080/02656736.2017.1291999] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
4 Van de Sande L, Rahimi-Gorji M, Giordano S, Davoli E, Matteo C, Detlefsen S, D'Herde K, Braet H, Shariati M, Remaut K, Xie F, Debbaut C, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W. Electrostatic Intraperitoneal Aerosol Delivery of Nanoparticles: Proof of Concept and Preclinical Validation. Adv Healthc Mater 2020;9:e2000655. [PMID: 32548967 DOI: 10.1002/adhm.202000655] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
5 Ceelen W, Demuytere J, de Hingh I. Hyperthermic Intraperitoneal Chemotherapy: A Critical Review. Cancers (Basel) 2021;13:3114. [PMID: 34206563 DOI: 10.3390/cancers13133114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Teja Surikutchi B, Obenza-Otero R, Russo E, Zelzer M, Golán Cancela I, Costoya JA, Crecente Campo J, José Alonso M, Marlow M. Development of a nanocapsule-loaded hydrogel for drug delivery for intraperitoneal administration. Int J Pharm 2022;:121828. [PMID: 35595041 DOI: 10.1016/j.ijpharm.2022.121828] [Reference Citation Analysis]
7 Wang P, Qu X, Che X, Luo Q, Tang X, Liu Y. Pharmaceutical strategies in improving anti-tumour efficacy and safety of intraperitoneal therapy for peritoneal metastasis. Expert Opin Drug Deliv 2021;18:1193-210. [PMID: 33682562 DOI: 10.1080/17425247.2021.1896493] [Reference Citation Analysis]
8 Hunt H, Simón-Gracia L, Tobi A, Kotamraju VR, Sharma S, Nigul M, Sugahara KN, Ruoslahti E, Teesalu T. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles. J Control Release 2017;260:142-53. [PMID: 28603028 DOI: 10.1016/j.jconrel.2017.06.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
9 Padmakumar S, Parayath N, Leslie F, Nair SV, Menon D, Amiji MM. Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices. Expert Opin Drug Deliv 2018;15:481-94. [PMID: 29488406 DOI: 10.1080/17425247.2018.1446938] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
10 Nowacki M, Peterson M, Kloskowski T, McCabe E, Guiral DC, Polom K, Pietkun K, Zegarska B, Pokrywczynska M, Drewa T, Roviello F, Medina EA, Habib SL, Zegarski W. Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. Oncotarget 2017;8:78208-24. [PMID: 29100461 DOI: 10.18632/oncotarget.20596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Hang Y, Tang S, Tang W, Větvička D, Zhang C, Xie Y, Yu F, Yu A, Sil D, Li J, Singh RK, Oupický D. Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer. J Control Release 2021;333:139-50. [PMID: 33774121 DOI: 10.1016/j.jconrel.2021.03.028] [Reference Citation Analysis]
12 Simón-Gracia L, Hunt H, Teesalu T. Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides. Molecules 2018;23:E1190. [PMID: 29772690 DOI: 10.3390/molecules23051190] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
13 Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K. Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis. Cancers (Basel) 2019;11:E906. [PMID: 31261685 DOI: 10.3390/cancers11070906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Carlier C, Mathys A, De Jaeghere E, Steuperaert M, De Wever O, Ceelen W. Tumour tissue transport after intraperitoneal anticancer drug delivery. Int J Hyperthermia 2017;33:534-42. [PMID: 28540828 DOI: 10.1080/02656736.2017.1312563] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
15 Suffian IFM, Wang JT, Faruqu FN, Benitez J, Nishimura Y, Ogino C, Kondo A, Al-Jamal KT. Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B Virus Core Nanoparticles for siRNA Delivery in Vitro and in Vivo. ACS Appl Nano Mater 2018;1:3269-82. [PMID: 30613831 DOI: 10.1021/acsanm.8b00480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kurtz F, Struller F, Horvath P, Solass W, Bösmüller H, Königsrainer A, Reymond MA. Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study. Gastroenterol Res Pract 2018;2018:2743985. [PMID: 30473706 DOI: 10.1155/2018/2743985] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
17 Wu X, Zhao G, He Y, Wang W, Yang CS, Zhang J. Pharmacological mechanisms of the anticancer action of sodium selenite against peritoneal cancer in mice. Pharmacol Res 2019;147:104360. [PMID: 31326526 DOI: 10.1016/j.phrs.2019.104360] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
18 Braet H, Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Van Walleghem T, Cornelis S, Cosyns S, Vervaet C, Willaert W, Ceelen W, De Smedt SC, Remaut K. Exploring High Pressure Nebulization of Pluronic F127 Hydrogels for Intraperitoneal Drug Delivery. Eur J Pharm Biopharm 2021:S0939-6411(21)00256-3. [PMID: 34634467 DOI: 10.1016/j.ejpb.2021.10.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Melchor-Martínez EM, Torres Castillo NE, Macias-Garbett R, Lucero-Saucedo SL, Parra-Saldívar R, Sosa-Hernández JE. Modern World Applications for Nano-Bio Materials: Tissue Engineering and COVID-19. Front Bioeng Biotechnol 2021;9:597958. [PMID: 34055754 DOI: 10.3389/fbioe.2021.597958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Dakwar GR, Braeckmans K, Ceelen W, De Smedt SC, Remaut K. Exploring the HYDRAtion method for loading siRNA on liposomes: the interplay between stability and biological activity in human undiluted ascites fluid. Drug Deliv and Transl Res 2017;7:241-51. [DOI: 10.1007/s13346-016-0329-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
21 Rahimi-gorji M, Van de Sande L, Debbaut C, Ghorbaniasl G, Braet H, Cosyns S, Remaut K, Willaert W, Ceelen W. Intraperitoneal aerosolized drug delivery: Technology, recent developments, and future outlook. Advanced Drug Delivery Reviews 2020;160:105-14. [DOI: 10.1016/j.addr.2020.10.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
22 Park EJ, Ahn J, Gwak SW, Park KS, Baik SH, Hwang SJ. Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model. Ann Surg Oncol 2018;25:3185-92. [PMID: 30027459 DOI: 10.1245/s10434-018-6628-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Takechi-haraya Y, Goda Y, Sakai-kato K. Atomic Force Microscopy Study on the Stiffness of Nanosized Liposomes Containing Charged Lipids. Langmuir 2018;34:7805-12. [DOI: 10.1021/acs.langmuir.8b01121] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
24 Xie Y, Hang Y, Wang Y, Sleightholm R, Prajapati DR, Bader J, Yu A, Tang W, Jaramillo L, Li J, Singh RK, Oupický D. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy. ACS Nano 2020;14:255-71. [PMID: 31927946 DOI: 10.1021/acsnano.9b03978] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
25 Xu G, Li B, Wang T, Wan J, Zhang Y, Huang J, Shen Y. Enhancing the anti-ovarian cancer activity of quercetin using a self-assembling micelle and thermosensitive hydrogel drug delivery system. RSC Adv 2018;8:21229-42. [DOI: 10.1039/c8ra03274b] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Ceelen W, Braet H, van Ramshorst G, Willaert W, Remaut K. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion. Expert Opin Drug Deliv 2020;17:511-22. [PMID: 32142389 DOI: 10.1080/17425247.2020.1736551] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
27 Kuper CF, Pieters RHH, van Bilsen JHM. Nanomaterials and the Serosal Immune System in the Thoracic and Peritoneal Cavities. Int J Mol Sci 2021;22:2610. [PMID: 33807632 DOI: 10.3390/ijms22052610] [Reference Citation Analysis]
28 Ando H, Abu Lila AS, Fukushima M, Matsuoka R, Shimizu T, Okuhira K, Ishima Y, Huang CL, Wada H, Ishida T. A simplified method for manufacturing RNAi therapeutics for local administration. Int J Pharm 2019;564:256-62. [PMID: 31015002 DOI: 10.1016/j.ijpharm.2019.04.054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Shamsi M, Sedaghatkish A, Dejam M, Saghafian M, Mohammadi M, Sanati-Nezhad A. Magnetically assisted intraperitoneal drug delivery for cancer chemotherapy. Drug Deliv 2018;25:846-61. [PMID: 29589479 DOI: 10.1080/10717544.2018.1455764] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 9.8] [Reference Citation Analysis]
30 De Clercq K, Xie F, De Wever O, Descamps B, Hoorens A, Vermeulen A, Ceelen W, Vervaet C. Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer. Sci Rep 2019;9:14881. [PMID: 31619730 DOI: 10.1038/s41598-019-51419-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
31 Van De Sande L, Graversen M, Hubner M, Pocard M, Reymond M, Vaira M, Cosyns S, Willaert W, Ceelen W. Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis - a phase I first-in-human study. Pleura Peritoneum 2018;3:20180112. [PMID: 30911657 DOI: 10.1515/pp-2018-0112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
32 Khomyakov V, Ryabov A, Ivanov A, Bolotina L, Utkina A, Volchenko N, Kaprin A. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2). Pleura Peritoneum 2016;1:159-66. [PMID: 30911619 DOI: 10.1515/pp-2016-0017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
33 Ding L, Tang S, Yu A, Wang A, Tang W, Jia H, Oupický D. Nanoemulsion-Assisted siRNA Delivery to Modulate the Nervous Tumor Microenvironment in the Treatment of Pancreatic Cancer. ACS Appl Mater Interfaces 2022. [PMID: 35188730 DOI: 10.1021/acsami.1c21997] [Reference Citation Analysis]
34 Gao Y, Liu L, Shen B, Chen X, Wang L, Wang L, Feng W, Huang C, Li F. Amphiphilic PEGylated Lanthanide-Doped Upconversion Nanoparticles for Significantly Passive Accumulation in the Peritoneal Metastatic Carcinomatosis Models Following Intraperitoneal Administration. ACS Biomater Sci Eng 2017;3:2176-84. [PMID: 33440565 DOI: 10.1021/acsbiomaterials.7b00416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
35 Kitayama J, Ishigami H, Yamaguchi H, Yamada J, Soma D, Miyato H, Kamei T, Lefor AK, Sata N. Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model. Pleura Peritoneum 2017;2:95-102. [PMID: 30911637 DOI: 10.1515/pp-2017-0002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Freund E, Miebach L, Stope MB, Bekeschus S. Hypochlorous acid selectively promotes toxicity and the expression of danger signals in human abdominal cancer cells. Oncol Rep 2021;45:71. [PMID: 33760187 DOI: 10.3892/or.2021.8022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Bakker MH, Grillaud M, Wu DJ, Fransen PKH, de Hingh IH, Dankers PYW. Cholesterol Modification of an Anticancer Drug for Efficient Incorporation into a Supramolecular Hydrogel System. Macromol Rapid Commun 2018;39:e1800007. [PMID: 29806084 DOI: 10.1002/marc.201800007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
38 Sarfarazi A, Lee G, Mirjalili SA, Phillips ARJ, Windsor JA, Trevaskis NL. Therapeutic delivery to the peritoneal lymphatics: Current understanding, potential treatment benefits and future prospects. Int J Pharm 2019;567:118456. [PMID: 31238102 DOI: 10.1016/j.ijpharm.2019.118456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
39 Henderson E, Huynh G, Wilson K, Plebanski M, Corrie S. The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers. Biomedicines 2021;9:1554. [PMID: 34829783 DOI: 10.3390/biomedicines9111554] [Reference Citation Analysis]
40 Van de Sande L, Cosyns S, Willaert W, Ceelen W. Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review. Drug Deliv 2020;27:40-53. [PMID: 31858848 DOI: 10.1080/10717544.2019.1704945] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
41 Kim HI, Wilson BC. Photodynamic Diagnosis and Therapy for Peritoneal Carcinomatosis from Gastrointestinal Cancers: Status, Opportunities, and Challenges. J Gastric Cancer 2020;20:355-75. [PMID: 33425438 DOI: 10.5230/jgc.2020.20.e39] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Shariati M, Lollo G, Matha K, Descamps B, Vanhove C, Van de Sande L, Willaert W, Balcaen L, Vanhaecke F, Benoit JP, Ceelen W, De Smedt SC, Remaut K. Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer. ACS Appl Mater Interfaces 2020;12:29024-36. [PMID: 32506916 DOI: 10.1021/acsami.0c05554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Trombino S, Servidio C, Curcio F, Cassano R. Strategies for Hyaluronic Acid-Based Hydrogel Design in Drug Delivery. Pharmaceutics 2019;11:E407. [PMID: 31408954 DOI: 10.3390/pharmaceutics11080407] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 18.7] [Reference Citation Analysis]
44 Le DHT, Méndez-López E, Wang C, Commandeur U, Aranda MA, Steinmetz NF. Biodistribution of Filamentous Plant Virus Nanoparticles: Pepino Mosaic Virus versus Potato Virus X. Biomacromolecules 2019;20:469-77. [PMID: 30516960 DOI: 10.1021/acs.biomac.8b01365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
45 Alavi S, Haeri A, Mahlooji I, Dadashzadeh S. Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy. Pharm Res 2020;37. [DOI: 10.1007/s11095-020-02818-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Chang CM, Lan KL, Huang WS, Lee YJ, Lee TW, Chang CH, Chuang CM. 188Re-Liposome Can Induce Mitochondrial Autophagy and Reverse Drug Resistance for Ovarian Cancer: From Bench Evidence to Preliminary Clinical Proof-of-Concept. Int J Mol Sci 2017;18:E903. [PMID: 28441355 DOI: 10.3390/ijms18050903] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
47 Zhao G, Dong R, Teng J, Yang L, Liu T, Wu X, He Y, Wang Z, Pu H, Wang Y. N-Acetyl-l-cysteine Enhances the Effect of Selenium Nanoparticles on Cancer Cytotoxicity by Increasing the Production of Selenium-Induced Reactive Oxygen Species. ACS Omega 2020;5:11710-20. [PMID: 32478262 DOI: 10.1021/acsomega.0c01034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Kim J, Shim MK, Cho YJ, Jeon S, Moon Y, Choi J, Kim J, Lee J, Lee JW, Kim K. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials 2021;279:121189. [PMID: 34695659 DOI: 10.1016/j.biomaterials.2021.121189] [Reference Citation Analysis]
49 Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 2021;7:91. [PMID: 34916522 DOI: 10.1038/s41572-021-00326-6] [Reference Citation Analysis]
50 Vos LMC, Aronson SL, van Driel WJ, Huitema ADR, Schagen van Leeuwen JH, Lok CAR, Sonke GS. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2021:S1521-6934(21)00104-8. [PMID: 34565676 DOI: 10.1016/j.bpobgyn.2021.06.004] [Reference Citation Analysis]
51 Liu D, Wang T, Lu Y. Untethered Microrobots for Active Drug Delivery: From Rational Design to Clinical Settings. Adv Healthc Mater 2021;:e2102253. [PMID: 34767306 DOI: 10.1002/adhm.202102253] [Reference Citation Analysis]
52 Shariati M, Zhang H, Van de Sande L, Descamps B, Vanhove C, Willaert W, Ceelen W, De Smedt SC, Remaut K. High Pressure Nebulization (PIPAC) Versus Injection for the Intraperitoneal Administration of mRNA Complexes. Pharm Res 2019;36:126. [PMID: 31236829 DOI: 10.1007/s11095-019-2646-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]